Tianhong CNI BIOMEDICINE ETF(159859) Drops 1.79%, Shares Grow by 140 Million over Past Week

NewTimeSpace News — As of 13:56 on April 23, 2026, Tianhong Biomedical ETF (159859) fell by 1.79%, with the latest quoted price at RMB 0.38. Looking back over a longer period, as of April 22, 2026, Tianhong Biomedical ETF had accumulated a gain of 6.56% over the past month. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Tianhong Biomedical ETF recorded an intraday turnover rate of 2.66%, with a trading volume of RMB 101 million. Looking back over a longer period, as of April 22, Tianhong Biomedical ETF had an average daily trading volume of RMB 140 million over the past month, ranking first among comparable funds.

In terms of scale, Tianhong Biomedical ETF's scale grew by RMB 34.7308 million over the past month, achieving significant growth, with the newly added scale ranking 1st out of 3 comparable funds. (Data source: Wind)

In terms of shares, Tianhong Biomedical ETF's shares grew by 140 million shares over the past week, achieving significant growth, with the newly added shares ranking 1st out of 3 comparable funds. (Data source: Wind)

From the perspective of net capital inflows, Tianhong Biomedical ETF has received continuous net capital inflows for the past four days, with the highest single-day net inflow reaching RMB 31.9471 million, totaling RMB 55.1237 million in "capital attraction," and an average daily net inflow of RMB 13.7809 million. (Data source: Wind)

Data shows that leveraged capital continues to position itself in the fund. Tianhong Biomedical ETF's latest margin purchase amount reached RMB 4.0771 million, and the latest margin balance reached RMB 164 million. (Data source: Wind)

As of April 22, Tianhong Biomedical ETF's net asset value (NAV) had risen by 15.13% over the past year, ranking first among comparable funds. In terms of return capability, as of April 22, 2026, since its establishment, Tianhong Biomedical ETF's highest monthly return was 27.87%, the longest consecutive rising months were 5 months, the longest consecutive rising gain was 31.58%, and the average return rate in rising months was 5.50%. As of April 22, 2026, Tianhong Biomedical ETF's annualized excess return over the benchmark since its establishment was 1.94%.

In terms of drawdown, as of April 22, 2026, Tianhong Biomedical ETF's year-to-date relative benchmark drawdown was 0.08%, representing the smallest drawdown among comparable funds.

In terms of fees, Tianhong Biomedical ETF's management fee rate is 0.50%, and the custody fee rate is 0.10%, representing the lowest fee level among comparable funds.

In terms of tracking accuracy, as of April 22, 2026, Tianhong Biomedical ETF's tracking error since the beginning of this year was 0.014%, indicating the highest tracking precision among comparable funds.

From a valuation perspective, the CNI Biomedical Index tracked by Tianhong Biomedical ETF has a latest price-to-earnings ratio (PE-TTM) of only 36.97x, standing at the 14.23rd percentile over the past year, meaning its valuation is lower than that of 85.77% of the time over the past year, placing it at a historical low.

Tianhong Biomedical ETF closely tracks the CNI Biomedical Index. The CNI Biomedical Index takes listed companies related to the biomedical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space, and selects the top 30 securities based on comprehensive rankings of market capitalization scale and liquidity as index constituent stocks, reflecting the overall operation of the biomedical industry and providing the market with index-based investment targets for this subdivision industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.